7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with zileuton in 1 studies
| Studies (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Trials (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Recent Studies (post-2010) (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Studies (zileuton) | Trials (zileuton) | Recent Studies (post-2010) (zileuton) |
|---|---|---|---|---|---|
| 39 | 15 | 14 | 551 | 64 | 193 |
| Protein | Taxonomy | 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid (IC50) | zileuton (IC50) |
|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | 0.6 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 1.4782 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | 0.9656 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | 0.4 | |
| Arachidonate 5-lipoxygenase-activating protein | Homo sapiens (human) | 0.58 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.591 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Mus musculus (house mouse) | 0.19 | |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | 0.42 | |
| Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | 0.42 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.42 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akpa, EG; Bosworth, BP; Boyle, JO; Brown, PH; Dannenberg, AJ; Duffield-Lillico, AJ; Kingsley, PJ; Knutson, A; Marnett, LJ; Milne, GL; Mohebati, A; Szabo, E; Zhou, XK | 1 |
1 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and zileuton
| Article | Year |
|---|---|
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Topics: Adult; Arachidonate 5-Lipoxygenase; Biomarkers; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Maximum Tolerated Dose; Prognosis; Prostaglandins; Pyrazoles; Smoking; Sulfonamides; Tandem Mass Spectrometry | 2013 |